Clinical Trials on Fibrostenotic Crohn's Disease in Australia

Total 13439 results

Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Pfizer

Completed

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Crohn's Disease

Korea, Republic of, United States, Spain, Netherlands, Australia, Israel, Canada, Czechia, Japan, Germany, Hungary, Austria, Bulgaria, Greece, South Africa, Ukraine, France
Odyssey Therapeutics

Recruiting

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis | Spondyloarthritis | Blau Syndrome

Australia
Genzyme, a Sanofi Company

Terminated

Open-label Trial of Leukine in Active Crohn's Disease

Crohn Disease

Switzerland, United States, New Zealand, Canada, Australia, Brazil, United Kingdom, Ukraine, Russian Federation, Argentina
Takeda

Completed

A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD) (CHRONOS)

Inflammatory Bowel Diseases | Crohn Disease | Colitis, Ulcerative

Austria
Abbott

Terminated

Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

Crohn's Disease

United States, Australia, Austria, Belgium, Canada, Denmark, Puerto Rico
TxCell

Terminated

Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease (CATS29)

Crohn Disease

Austria, France, Belgium, United Kingdom, Germany, Italy
Pfizer

Completed

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Crohn's Disease

United States, Spain, Israel, Netherlands, Australia, Canada, Japan, Germany, Korea, Republic of, Hungary, Austria, Bulgaria, Czech Republic, Greece, South Africa, Ukraine, France
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

Spain, United Kingdom, United States, France, Italy, Germany, New Zealand, Australia, Poland, South Africa, Hungary, Canada, Czechia
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
Groupe d'Etude Therapeutique des Affections Inflammatoires...
Saint-Louis Hospital, Paris, France

Completed

A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy (SPARE)

Crohn's Disease

Australia, Belgium, France
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (CARMEN CD 305)

Crohn's Disease

United States, Australia, Romania, Israel, Italy, Croatia, South Africa, Germany, Poland, United Kingdom, Austria, Japan, Lithuania, Netherlands, Russian Federation, Serbia
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Abbott

Completed

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Crohn's Disease

United States, Germany, Belgium, Canada, Netherlands, Italy, Austria, France
UCB BIOSCIENCES GmbH
PPD

Completed

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Crohn Disease

Russian Federation, Belgium, United States, Australia, Austria, Brazil, Canada, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, New Zealand, Poland, Romania, Ukraine
Theravance Biopharma

Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Crohn's Disease

United States, Bulgaria, France, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Portugal, Romania, Serbia, South Africa, Spain, Ukraine, Australia, Austria, Croatia, New Zealand, Russian Federation, United...
AbbVie

Terminated

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (AIM-CD)

Crohn's Disease

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, Spain, Taiwan, United...
GlaxoSmithKline

Terminated

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (SHIELD-4)

Crohn's Disease

United States, France, Netherlands, Spain, Taiwan, Bulgaria, Germany, Poland, Ukraine, Belgium, Israel, Korea, Republic of, Australia, Austria, Canada, Chile, Czechia, Denmark, Estonia, Hong Kong, Hungary, Italy, Japan, New Zealand, Por... and more
Hoffmann-La Roche

Terminated

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 (JUNIPER)

Crohn Disease

United States, Israel, Spain, United Kingdom, Canada, Australia, Austria, Czechia, France, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Korea, Republic of, Germany, Bulgaria, Croatia, Hungary, Poland, Ukraine and more
Hoffmann-La Roche

Completed

A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease (BERGAMOT)

Crohn Disease

United States, Israel, Spain, United Kingdom, Korea, Republic of, Canada, Australia, Austria, Czechia, France, Hungary, Italy, Netherlands, New Zealand, Russian Federation, Belgium, Brazil, Argentina, Bulgaria, Croatia, Germany, P... and more
Genzyme, a Sanofi Company

Terminated

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Crohn Disease

Israel, United States, Romania, Ukraine, South Africa, Canada, Australia, Bulgaria, Russian Federation, New Zealand, Brazil
Abbott

Completed

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Crohn's Disease

United States, Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, South Africa, Spain, Sweden, United Kingdom
Provention Bio, Inc.

Completed

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease (PRINCE)

Crohn's Disease

Austria, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
Medtronic - MITG

Completed

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease. (BLINK)

Crohn Disease

United States, Israel, Austria
Tigenix S.A.U.

Completed

Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease (ADMIRE-CD)

Crohn's Disease

Spain, Belgium, Netherlands, France, Israel, Italy, Austria, Germany
Pfizer

Completed

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

Korea, Republic of, Canada, United States, Spain, Netherlands, Australia, Israel, Croatia, Japan, Germany, Hungary, Bulgaria, Austria, Czech Republic, France, Greece, South Africa, Ukraine
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease (SERENITY)

Crohn's Disease

United States, Belgium, Netherlands, Australia, Hungary, United Kingdom, Czechia, Poland, Switzerland, Japan, Romania, Ukraine, Russian Federation, Canada
Shire

Completed

Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs (TOSCA)

Crohn's Disease | Ulcerative Colitis | Ileitis | Granulomatous Colitis | Ileo-colonic and Colonic Crohn's Disease | Regional Enteritis

France, Belgium, Austria, Germany, Netherlands
Celgene

Terminated

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Crohn's Disease

United States, Korea, Republic of, Spain, Netherlands, Belgium, Australia, Austria, Denmark, United Kingdom, Hungary, Israel, Portugal, Canada, Germany, Italy, Croatia, Czechia, Greece, Russian Federation, Serbia, Slovakia, Ukraine, Polan... and more
Takeda

Completed

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

Crohn's Disease

Belgium, Israel, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Hungary, Serbia, Bulgaria, Canada, Germany, Italy, Poland, Slovakia, Czechia, Mexico, Romania, Brazil, Estonia, United States, Bosnia and Herzegovina and more
Celgene

Withdrawn

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Crohn Disease

United States, Spain, Belgium, Denmark, Canada, Australia, Austria, United Kingdom, Netherlands, Italy, Korea, Republic of, Germany, Portugal, Croatia, Czechia, Greece, Hungary, Israel, Poland, Russian Federation, Serbia, Slovakia, ... and more
Celgene

Completed

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Spain, Australia, Austria, Bulgaria, Canada, China, Colombia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Se... and more
Celgene

Terminated

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

Crohn Disease

United States, Korea, Republic of, Netherlands, Spain, Belgium, Denmark, Australia, Austria, Russian Federation, United Kingdom, Croatia, Canada, Italy, Hungary, Israel, Portugal, Serbia, Poland, Germany, France, Czechia, Greece, Sl... and more
UCB Celltech

Terminated

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (NURTURE)

Crohn's Disease

United States, Canada, New Zealand, Australia
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) (CARMEN CD 307)

Crohn's Disease

Spain, United States, Korea, Republic of, Australia, Romania, Hungary, Israel, Italy, Croatia, Belgium, Bulgaria, Germany, Poland, Portugal, Argentina, United Kingdom, Greece, New Zealand, Austria, Bosnia and Herzegovina, Colombia, Eston... and more
Ventyx Biosciences, Inc

Active, not recruiting

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease (Harmony-CD)

Crohn Disease

United States, Australia, Brazil, Bulgaria, Canada, Czechia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Moldova, Republic of, Poland, Slovakia
VHsquared Ltd.

Completed

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease (HarbOR)

Crohn's Disease

United States, Germany, Canada, Hungary, Poland, Serbia, United Kingdom, Netherlands, Ukraine, Austria, Norway, Slovakia, Czechia
CSL Behring

Terminated

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease

Germany, India, Korea, Republic of, Taiwan, United States, Hong Kong, Canada, Mexico, Austria, Switzerland, Israel, Italy, France, Poland, Netherlands, Hungary, Czechia, United Kingdom
Pfizer

Completed

B0151005 Open-Label Extension Study (ANDANTE II)

Crohn's Disease

United States, Denmark, Israel, Ireland, Australia, Czechia, Canada, United Kingdom, Hungary, Germany, New Zealand, Brazil, Switzerland, Belgium, France, Italy
RedHill Biopharma Limited

Completed

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease (MAPUS)

Crohn's Disease

United States, New Zealand, Australia, Bulgaria, Canada, Czechia, Israel, Poland, Serbia, Slovakia
Eli Lilly and Company

Recruiting

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

Crohn's Disease

United States, Australia, China, Korea, Republic of, Canada, Denmark, India, Turkey, Ukraine, Japan, Brazil, Mexico, Israel, Croatia, Hungary, Latvia, Lithuania, Serbia, Poland, Czechia, Slovakia, Switzerland, Russian Federation, Germany and more
Celgene

Active, not recruiting

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Crohn Disease

United States, Italy, Germany, Russian Federation, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Finland, France, Georgia, India, Ireland, Israel, Korea, Republic... and more
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (POWER)

Crohn Disease

United States, Korea, Republic of, Netherlands, France, Austria, Italy, United Kingdom, Germany, Russian Federation, Spain, Czechia, Sweden
AbbVie

Active, not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
Shire

Completed

A Study To Monitor Long-Term Treatment With PF-00547659 (OPERA II)

Crohn's Disease

Korea, Republic of, United States, Spain, France, Serbia, Netherlands, Germany, Japan, Austria, Belgium, Poland, Canada, Norway, Slovakia, South Africa
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
AbbVie

Completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (U-EXCEL)

Crohn's Disease

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy and more
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (SHIELD-1)

Crohn's Disease

United States, France, Netherlands, Spain, Germany, Poland, Belgium, South Africa, Sweden, Israel, Korea, Republic of, Australia, Austria, Canada, Czechia, Denmark, Hungary, Italy, Japan, New Zealand, Norway, Slovakia, United Kingdom
Medical University of Graz

Completed

Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases

Crohn's Disease | Ulcerative Colitis | Colon Cancer

Austria

Clinical Trials on Fibrostenotic Crohn's Disease in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations